Artificial intelligence (AI) tools are increasingly integrated into hepatology clinical practice and training, such as ambient scribes and note drafting in clinic, chart summarization on consult services, and AI–enabled platforms that synthesize evidence for point-of-care questions. While these tools may accelerate access to knowledge, they also introduce important educational and professional risks: (1) Trainees may become overly reliant on AI and never fully acquire core clinical skills, (2) AI–generated recommendations may be accepted without appropriate verification or contextualization, and (3) evolving boundaries on AI usage in scholarly pursuits and research. 

Presented as a partnership between the Clinical Informatics and Digital Health Special Interest Group and the Training and Workforce Committee, this program provides a hepatology-centered framework for responsible AI use across 3 domains: enhancing hepatology education quality; using AI to enhance self-directed learning and evidence appraisal; and establishing guardrails for scholarly use of AI to maintain academic integrity. The session concludes with an interactive panel discussion using common scenarios to translate principles into implementable teaching strategies and program policies.

Every day scientists make exciting discoveries that have the potential to improve human health. The path to the clinic, however, can be challenging. In this session, scientist-physician pairs give short presentations summarizing how they took their discoveries from the bench to the bedside. The scientist discusses the process of drug discovery, development, and testing. The clinician discusses how to identify promising preclinical therapies for patients and partner with scientists to establish clinical trials. Both pairs talk about the importance of finding the right partner in order to translate preclinical findings to patients. The program concludes with a panel discussion and question-and-answer period.

The landscape of hepatocellular carcinoma (HCC) treatment options has changed dramatically in recent years. There is also increasing recognition of the importance of incorporating patient values, preferences, and patient-reported outcomes (PROs), including health-related quality of life (HRQOL), into treatment decisions. In light of these changes, the Barcelona Clinic Liver Cancer (BCLC)—which previously advocated a strict treatment algorithm—now endorses the CUSE decision framework incorporating complexity, uncertainty, subjectivity, and emotion. Utilizing more flexible decision frameworks such as CUSE remains most feasible in co-located multidisciplinary HCC clinics but may be more challenging outside of these settings where many patients with HCC receive care.

This session aims to provide practical guidance on best practices for assessing patient preferences, monitoring and incorporating PROs, and applying more flexible treatment decision frameworks. These concepts are practiced through an interactive, case-based activity to provide hands-on experience with patient-informed treatment decision-making in common clinical scenarios.

Join journal editors from Hepatology, Hepatology Communications, and Liver Transplantation for an interactive community conversation tailored to residents, fellows, junior faculty, and students. Expect a pragmatic mix of brief talks and an extended open discussion focused on how to craft compelling manuscripts, what editors look for in submissions and review articles (basic and clinical), and how to navigate decisions and revisions with confidence. The editors emphasize practical takeaways that you can apply immediately to your interaction with journals.

Diversity, equity, and inclusion (DEI) efforts in hepatology face growing pressure from shifting political, regulatory, and funding environments, despite ongoing disparities. This session outlines a 3-part practical playbook. Presenters begin by reviewing strategic design of clinical trials to improve inclusivity. Next, faculty review best practices in sustainable collaboration with community organizations and patient advocacy partners, despite intensifying funding challenges. The program concludes with an evaluation of the impact and challenges of dedicated DEI sections in leading gastroenterology and hepatology journals, and how to advance more equitable authorship and dissemination. A facilitated discussion translates these insights into actionable local strategies.

This informative session enables attendees to gain knowledge of the new 2026 American Board of Internal Medicine maintenance of certification requirements and updates, along with newly available pathways and strategies to more effectively prepare for certification.

The popular Liver Fellow Network's "Ask Me Anything" session returns again to The Liver Meeting as both a networking and advising session. Using a small-group discussion format, faculty and liver fellows address topics regarding pathways to hepatology training, research opportunities, networking, finding a training position or job, and other questions attendees may have about entering the field of hepatology. 

This community conversation explores the complex interplay between immunosuppression and the immune system in liver transplantation settings. Expert panelists discuss strategies for safe immunosuppression minimization amid rejection risks, the evolving role of immunotherapy in persons with hepatocellular carcinoma awaiting transplant, and cautious approaches to immunotherapy for de novo malignancies post liver transplant. Attendees gain practical insights into balancing tolerance, rejection management, and oncologic care in contemporary practice.

Alcohol-associated liver disease (ALD) is evolving faster than our clinical paradigms. Women are developing severe ALD at unprecedented rates despite lower alcohol consumption levels. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer tantalizing dual benefits for cravings and steatosis. Traditional screening tools may miss high-functioning patients with metabolic risk.

This rapid-fire community conversation tackles 4 critical questions hepatologists face daily, moving from, "Is there a safe drinking limit?" to, "Why do systemic barriers prevent integrated alcohol use disorder care?" Four expert discussants present emerging data and clinical realities in focused segments, followed by an open panel discussion and audience questions and answers for crosscutting synthesis.

Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the most common chronic liver disease in children. Yet no pharmacotherapies are currently approved for pediatric use. Despite rapid advances in adult MASLD/metabolic dysfunction–associated steatohepatitis (MASH) drug development, translation/extrapolation to pediatric populations remains limited due to biologic differences, ethical considerations, feasibility challenges, and regulatory uncertainty.

This session convenes regulatory leaders, pediatric clinical trial experts, and translational investigators to clarify pathways for pediatric MASLD drug development and approval. Through short, focused presentations and an interactive panel discussion, the presenters highlight strategies to align trial design, biomarker development, and regulatory expectations to accelerate safe and effective therapies for MASLD in children.